CA3203773A1 - Methods and materials for treating t cell cancers - Google Patents

Methods and materials for treating t cell cancers

Info

Publication number
CA3203773A1
CA3203773A1 CA3203773A CA3203773A CA3203773A1 CA 3203773 A1 CA3203773 A1 CA 3203773A1 CA 3203773 A CA3203773 A CA 3203773A CA 3203773 A CA3203773 A CA 3203773A CA 3203773 A1 CA3203773 A1 CA 3203773A1
Authority
CA
Canada
Prior art keywords
polypeptide
seq
cell
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3203773A
Other languages
English (en)
French (fr)
Inventor
Sarah DINAPOLI
Jacqueline DOUGLASS
Emily Han-Chung HSIUE
Michael S. HWANG
Kenneth W. Kinzler
Maximilian KONIG
Brian J. MOG
Nickolas Papadopoulos
Andrew M. PARDOLL
Suman PAUL
Alexander H. PEARLMAN
Bert Vogelstein
Shibin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA3203773A1 publication Critical patent/CA3203773A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3203773A 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers Pending CA3203773A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119753P 2020-12-01 2020-12-01
US63/119,753 2020-12-01
PCT/US2021/061453 WO2022119955A1 (en) 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers

Publications (1)

Publication Number Publication Date
CA3203773A1 true CA3203773A1 (en) 2022-06-09

Family

ID=79021888

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3203773A Pending CA3203773A1 (en) 2020-12-01 2021-12-01 Methods and materials for treating t cell cancers

Country Status (7)

Country Link
US (1) US20240002541A1 (https=)
EP (1) EP4255482A1 (https=)
JP (1) JP2023551535A (https=)
CN (1) CN116867519A (https=)
AU (1) AU2021392655A1 (https=)
CA (1) CA3203773A1 (https=)
WO (1) WO2022119955A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
WO2024102980A1 (en) * 2022-11-11 2024-05-16 Pasithea Therapeutics Corp. Anti-alpha5 integrin antibodies and uses thereof
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025247325A1 (en) * 2024-05-30 2025-12-04 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibody-drug conjugates targeting trbv12 and uses thereof
WO2026011103A1 (en) * 2024-07-03 2026-01-08 Yale University Tcr-vβeta specific therapeutic molecules and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
JP2018517712A (ja) * 2015-06-01 2018-07-05 メディジーン イミュノテラピーズ ゲーエムベーハー Ｔ細胞受容体特異的抗体
EP3192810A1 (en) * 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
AU2018269370B2 (en) * 2017-05-16 2025-06-05 The Johns Hopkins University Manabodies and methods of using
CA3105448A1 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
JP7737306B2 (ja) * 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
EP3927431A1 (en) * 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof

Also Published As

Publication number Publication date
WO2022119955A1 (en) 2022-06-09
CN116867519A (zh) 2023-10-10
AU2021392655A9 (en) 2024-05-02
AU2021392655A1 (en) 2023-06-22
EP4255482A1 (en) 2023-10-11
US20240002541A1 (en) 2024-01-04
JP2023551535A (ja) 2023-12-08

Similar Documents

Publication Publication Date Title
AU2019218989B2 (en) Chimeric antigen receptors targeting the tumor microenvironment
JP7208010B2 (ja) 癌を標的とするキメラ抗原受容体
KR102809774B1 (ko) 합성 면역 수용체 및 이의 사용 방법
US20240002541A1 (en) Methods and materials for treating t cell cancers
US20220135678A1 (en) Methods and compositions to improve the safety and efficacy of cellular therapies
TWI654206B (zh) 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
TW202016139A (zh) Bcma 嵌合抗原受體及其用途
TW201806619A (zh) 嵌合抗原受體及pd-1抑制劑之組合療法
CN110520524A (zh) 靶向肿瘤微环境的嵌合抗原受体t细胞
JP2021525509A (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
JP2020533958A (ja) 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法
CN112292140B (zh) 靶向cd37和cd19的嵌合抗原受体
CN110461363B (zh) 靶向cd37的嵌合抗原受体
US20190134095A1 (en) Compositions and methods for improved nk cell therapies
US20230322923A1 (en) Methods and compositions relating to ex vivo culture and modulation of t cells
US20220347214A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
JP2024514149A (ja) ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用
WO2022020720A9 (en) Compositions and methods for treating cancer
US20230065936A1 (en) Compositions and methods for treating cancer
WO2023044039A1 (en) Compositions and methods for treating cancer
RU2815417C2 (ru) Лечение злокачественной опухоли с использованием химерного рецептора антигена против cd19

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241122

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251121

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251121

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251126

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260121

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122